8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 23, 2026·SEC
BioAtla, Inc.(BCAB)Earnings, Financials & Key Ratios
BCAB•NASDAQ
$4.58
Price updated Jul 6, 2026
AboutBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Show more
- Revenue$2M-81.8%
- EBITDA-$59M+19.3%
- Net Income-$60M+14.6%
- EPS (Diluted)-50.50+29.9%
- Gross Margin100%+9.2%
- EBITDA Margin-2946.6%-343.9%
- Operating Margin-2965.25%-341.1%
- Net Margin-2980.35%-369.8%
BCAB Price & Volume
BioAtla, Inc. (BCAB) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Burn Threatens Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion risk
Key Thesis Takeaways
- BioAtla faces an existential liquidity crisis as its clinical-stage business model fails to generate sustainable revenue, evidenced by a TTM revenue of only $2.0 million.
- The company's reliance on non-recurring milestone payments has left it with a $37.3 million equity deficit and a rapidly depleting cash reserve of $2.0 million as of 2026Q1.
- Investors should exercise extreme caution, as the firm's inability to achieve positive operating leverage suggests that further dilutive financing or a restructuring event may be imminent.
Verdict Logic
the company's cash position has dwindled to $2.0 million against a quarterly burn rate that necessitates immediate and likely dilutive capital intervention to maintain operations.
BCAB Growth Metrics
BioAtla, Inc. (BCAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years36.06%
3 Years-
TTM-81.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM31.61%
Return on Capital
10 Years-157.68%
5 Years-138.7%
3 Years-200.3%
Last Year-398.18%
BCAB Recent Earnings
BioAtla, Inc. (BCAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 31, 2026Metric
Actual
Est
EPS
$8.00+33.3%
$12.00
Rev
$2M+185.7%
$700,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.27+12.9%
$0.31
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.31-6.9%
$0.29
Rev
—
—
Q2 2025
May 6, 2025Metric
Actual
Est
EPS
$0.29-3.6%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $8.00vs $12.00+33.3% | $2Mvs $700,000+185.7% |
| Q4 2025 | Nov 13, 2025 | $0.27vs $0.31+12.9% | — |
| Q3 2025 | Aug 7, 2025 | $0.31vs $0.29-6.9% | — |
| Q2 2025 | May 6, 2025 | $0.29vs $0.28-3.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioAtla, Inc. (BCAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.58 | $5.78M | -0.09 | -81.82% | -2980.35% | — | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — | |
| $2.99 | $348.51M | -2.60 | -51.24% | -2056.79% | -58.89% | — |
Compare BCAB vs Peers
BioAtla, Inc. (BCAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCAB SEC Filings & Documents
BioAtla, Inc. (BCAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BCAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCAB Frequently Asked Questions
BioAtla, Inc. (BCAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BioAtla, Inc.'s revenue?
BioAtla, Inc. (BCAB) reported $2.0M in revenue for fiscal year 2025. This represents a 81% decrease from $10.6M in 2018.
How fast is BioAtla, Inc. growing?
BioAtla, Inc. (BCAB) saw revenue decline by 81.8% over the past year.
Is BCAB profitable?
BioAtla, Inc. (BCAB) reported a net loss of $50.6M for fiscal year 2025.
Dividend & Returns
What is BioAtla, Inc.'s free cash flow?
BioAtla, Inc. (BCAB) had negative free cash flow of $23.1M in fiscal year 2025, likely due to heavy capital investments.